Prosemble has been awarded funding through the Innovate UK Biomedical Catalyst (BMC) Femtech & AI in Health: Feasibility Competition 2025.
The grant will support research into targeted drug delivery for EGFR-positive lung cancer using protein nanoparticles and artificial intelligence.
Innovate UK, part of UK Research and Innovation (UKRI), is the UK’s innovation agency. It aims to create a better future by inspiring, involving, and investing in businesses developing life-changing innovations, helping companies grow through the development and commercialisation of new products, processes, and services within a dynamic and inclusive innovation ecosystem.